查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2153405

全球胃癌治療市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

Global Stomach Cancer Treatment Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 242 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球胃癌治療市場預計將從2025年的65.6億美元成長至2034年的199.1億美元，2026年至2034年的複合年成長率（CAGR）為13.13%。該市場持續成長的原因是腫瘤學領域的進步，這些進步拓展了胃癌患者的治療選擇。治療方案包括手術、化療、特定情況下的放射線治療、標靶治療和免疫療法，取決於腫瘤的分期和特徵。人們對胃癌的認知不斷提高、診斷技術的改進以及獲得專業腫瘤服務的機會增加，都推動了治療需求的成長。醫療專業人員也越來越重視識別有助於治療選擇的分子層次特徵。這些趨勢正在推動藥物研發和投資，以開發更個人化的胃癌治療策略。

市場成長的驅動力來自癌症治療領域的創新、臨床研究活動的活性化以及生物標記檢測的廣泛應用。製藥公司正在開發針對胃癌相關特定蛋白質、基因突變和免疫路徑的療法。外科技術的改進和多學科治療方案的發展也有助於醫療團隊更有效地協調治療。診斷實驗室正在提升其識別可能影響治療決策的生物標記的能力。此外，研究機構、生技公司和醫療服務提供者之間的合作也為臨床試驗和新療法組合的評估提供了支持。

該市場的未來前景取決於更有效療法的研發、疾病的早期發現以及精準腫瘤學服務的普及。聯合免疫療法、標靶治療和分子水平療法的研究有望為合格的患者提供更多選擇。液態生物檢體和腫瘤分析技術的進步也將有助於治療監測和抗藥性機制的識別。然而，治療費用、副作用、診斷延遲以及獲得先進腫瘤學服務的機會不均等問題仍然是重大挑戰。持續的臨床研究、支持治療的改進以及診斷檢測的廣泛應用對於未來的市場發展至關重要。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：本節詳細評估影響市場成長的主要促進因素、阻礙因素、機會和挑戰。內容涵蓋技術發展、法律規範以及不斷變化的行業趨勢等因素。

市場區隔分析：本部分根據產品類型、應用、最終用戶和地區將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭趨勢和主要參與者所採取的策略。

市場預測：本部分提供基於數據的市場規模和成長模式預測，預測期為特定時期。它綜合考慮了歷史趨勢、當前市場狀況和定量分析，以識別未來預期趨勢。

區域分析：這包括對主要地理區域的市場表現進行全面檢驗，確定高成長地區和區域趨勢，以更深入地了解區域市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的報告客製化服務，以滿足您的特定需求。這包括額外的細分、國家/地區分析、競爭對手分析、客製化資料點或針對特定細分市場的洞察，以更好地支援您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章 全球胃癌治療市場：依治療類型分類

  • 市場分析、洞察與預測
  • 免疫療法
  • 標靶治療
  • 化療
  • 放射線治療和手術（僅定性分析）

第5章：全球胃癌治療市場：依疾病適應症分類

  • 市場分析、洞察與預測
  • 胃癌/胃食道交界處癌
  • 胃腸道基質腫瘤

第6章：全球胃癌治療市場：依給藥途徑分類

  • 市場分析、洞察與預測
  • 口服
  • 注射藥物

第7章 全球胃癌治療市場：依藥物類別分類

  • 市場分析、洞察與預測
  • PD-1/PD-L1抑制劑
  • HER2拮抗劑
  • VEGFR2拮抗劑
  • 其他

第8章：全球胃癌治療市場：依通路分類

  • 市場分析、洞察與預測
  • 醫院藥房
  • 專科藥房和零售藥房
  • 其他

第9章 全球胃癌治療市場：依地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 中國
    • 日本
    • 韓國
    • 印度
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第10章 競爭格局

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第11章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Merck & Co
    • Bristol Myers Squibb
    • AstraZeneca
    • Astellas Pharma
    • Roche
    • Eli Lilly
    • BeiGene
    • Daiichi Sankyo
    • Zymeworks
    • Amgen
    • Novartis
    • Pfizer
    • Sanofi
    • Takeda
    • Servier
    • Jiangsu Hengrui Medicine
    • Jiangsu Chia Tai Tianqing
    • Innovent Biologics
    • Eisai
    • Regeneron Pharmaceuticals
簡介目錄
Product Code: VMR112110032

The global stomach cancer treatment market size is expected to reach USD 19.91 Billion in 2034 from USD 6.56 Billion in 2025, growing at a CAGR of 13.13% during 2026-2034.This market is expanding as advances in oncology improve the range of treatment options available for patients diagnosed with stomach cancer. Treatment approaches may include surgery, chemotherapy, radiation therapy in selected cases, targeted therapies, and immunotherapy, depending on the disease stage and tumor characteristics. Increasing awareness of gastric cancer, improvements in diagnostic procedures, and broader access to specialist oncology services are supporting treatment demand. Healthcare providers are also placing greater emphasis on identifying molecular characteristics that can help guide therapy selection. These developments are encouraging pharmaceutical research and investment in more individualized stomach cancer treatment strategies.

Market growth is driven by innovations in cancer medicines, increasing clinical research activity, and the expanding use of biomarker testing. Pharmaceutical companies are developing therapies that target specific proteins, genetic alterations, and immune pathways associated with stomach cancer. Improved surgical techniques and multidisciplinary treatment planning are also helping healthcare teams coordinate care more effectively. Diagnostic laboratories are expanding their capabilities to identify biomarkers that may influence treatment decisions. Furthermore, collaborations between research institutions, biotechnology companies, and healthcare providers are supporting clinical trials and the evaluation of new therapeutic combinations.

The future prospects of this market will depend on the development of more effective treatments, earlier disease detection, and broader access to precision oncology. Research into immunotherapy combinations, targeted medicines, and molecularly guided treatment selection may provide additional options for eligible patients. Advances in liquid biopsy and tumor profiling could also support treatment monitoring and the identification of resistance mechanisms. However, treatment costs, adverse effects, late diagnosis, and differences in access to advanced oncology services remain significant challenges. Continued clinical research, improved supportive care, and greater availability of diagnostic testing will be important for future market development.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Treatment Type

  • Immunotherapy
  • Targeted Therapy
  • Chemotherapy
  • Radiation Therapy And Surgery (Qualitative Analysis Only)

By Disease Indication

  • Gastric Cancer/Gastroesophageal Junction Cancer
  • Gastrointestinal Stromal Tumors

By Route Of Administration

  • Oral
  • Injectable

By Drug Class

  • PD-1/PD-L1 Inhibitors
  • HER2 Antagonists
  • VEGFR2 Antagonists
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Specialty & Retail Pharmacies
  • Others

COMPANIES PROFILED

  • Merck & Co., Bristol Myers Squibb, AstraZeneca, Astellas Pharma, Roche, Eli Lilly, BeiGene, Daiichi Sankyo, Zymeworks, Amgen, Novartis, Pfizer, Sanofi, Takeda, Servier, Jiangsu Hengrui Medicine, Jiangsu Chia Tai Tianqing, Innovent Biologics, Eisai, Regeneron Pharmaceuticals

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL STOMACH CANCER TREATMENT MARKET: BY TREATMENT TYPE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Treatment Type
  • 4.2. Immunotherapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Targeted Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Chemotherapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Radiation Therapy And Surgery (Qualitative Analysis Only) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL STOMACH CANCER TREATMENT MARKET: BY DISEASE INDICATION 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Disease Indication
  • 5.2. Gastric Cancer/Gastroesophageal Junction Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Gastrointestinal Stromal Tumors Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL STOMACH CANCER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Route Of Administration
  • 6.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL STOMACH CANCER TREATMENT MARKET: BY DRUG CLASS 2022-2034 (USD MN)

  • 7.1. Market Analysis, Insights and Forecast Drug Class
  • 7.2. PD-1/PD-L1 Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.3. HER2 Antagonists Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.4. VEGFR2 Antagonists Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL STOMACH CANCER TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

  • 8.1. Market Analysis, Insights and Forecast Distribution Channel
  • 8.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 8.3. Specialty & Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 8.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL STOMACH CANCER TREATMENT MARKET: BY REGION 2022-2034 (USD MN)

  • 9.1. Regional Outlook
  • 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.2.1 By Treatment Type
    • 9.2.2 By Disease Indication
    • 9.2.3 By Route Of Administration
    • 9.2.4 By Drug Class
    • 9.2.5 By Distribution Channel
    • 9.2.6 United States
    • 9.2.7 Canada
    • 9.2.8 Mexico
  • 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.3.1 By Treatment Type
    • 9.3.2 By Disease Indication
    • 9.3.3 By Route Of Administration
    • 9.3.4 By Drug Class
    • 9.3.5 By Distribution Channel
    • 9.3.6 United Kingdom
    • 9.3.7 France
    • 9.3.8 Germany
    • 9.3.9 Italy
    • 9.3.10 Spain
    • 9.3.11 Russia
    • 9.3.12 Rest Of Europe
  • 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.4.1 By Treatment Type
    • 9.4.2 By Disease Indication
    • 9.4.3 By Route Of Administration
    • 9.4.4 By Drug Class
    • 9.4.5 By Distribution Channel
    • 9.4.6 China
    • 9.4.7 Japan
    • 9.4.8 South Korea
    • 9.4.9 India
    • 9.4.10 Australia
    • 9.4.11 South East Asia
    • 9.4.12 Rest Of Asia Pacific
  • 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.5.1 By Treatment Type
    • 9.5.2 By Disease Indication
    • 9.5.3 By Route Of Administration
    • 9.5.4 By Drug Class
    • 9.5.5 By Distribution Channel
    • 9.5.6 Brazil
    • 9.5.7 Argentina
    • 9.5.8 Peru
    • 9.5.9 Chile
    • 9.5.10 Rest of Latin America
  • 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.6.1 By Treatment Type
    • 9.6.2 By Disease Indication
    • 9.6.3 By Route Of Administration
    • 9.6.4 By Drug Class
    • 9.6.5 By Distribution Channel
    • 9.6.6 Saudi Arabia
    • 9.6.7 UAE
    • 9.6.8 Israel
    • 9.6.9 South Africa
    • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

  • 10.1. Recent Developments
  • 10.2. Company Categorization
  • 10.3. Supply Chain & Channel Partners (based on availability)
  • 10.4. Market Share & Positioning Analysis (based on availability)
  • 10.5. Vendor Landscape (based on availability)
  • 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL STOMACH CANCER TREATMENT INDUSTRY

  • 11.1. Top Companies Market Share Analysis
  • 11.2. Company Profiles
    • 11.2.1 Merck & Co
    • 11.2.2 Bristol Myers Squibb
    • 11.2.3 AstraZeneca
    • 11.2.4 Astellas Pharma
    • 11.2.5 Roche
    • 11.2.6 Eli Lilly
    • 11.2.7 BeiGene
    • 11.2.8 Daiichi Sankyo
    • 11.2.9 Zymeworks
    • 11.2.10 Amgen
    • 11.2.11 Novartis
    • 11.2.12 Pfizer
    • 11.2.13 Sanofi
    • 11.2.14 Takeda
    • 11.2.15 Servier
    • 11.2.16 Jiangsu Hengrui Medicine
    • 11.2.17 Jiangsu Chia Tai Tianqing
    • 11.2.18 Innovent Biologics
    • 11.2.19 Eisai
    • 11.2.20 Regeneron Pharmaceuticals